mIRIS

The mIRIS regimen is a combination chemotherapy protocol consisting of irinotecan and S-1, an oral multi-component fluoropyrimidine. Irinotecan is a semi-synthetic derivative of camptothecin that acts as a DNA topoisomerase I inhibitor, inducing lethal double-strand DNA breaks during the S-phase of the cell cycle. S-1 is a combination drug containing tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor that increases the bioavailability of 5-FU), and oteracil potassium (an orotate phosphoribosyltransferase inhibitor that reduces 5-FU-induced gastrointestinal toxicity). This regimen is frequently utilized in East Asian clinical practice for gastrointestinal malignancies. In the context of research at Fudan University, mIRIS is being evaluated in a Phase 2 clinical trial (NCT04176393) as a chemotherapy backbone in combination with the PD-1 inhibitor camrelizumab and the HER2-targeted antibody trastuzumab for patients with HER2-positive advanced colorectal cancer.

Brand names

TiggioCamptosar

Other names

modified IRISirinotecan plus S-1irinotecan + S-1TS-1 plus irinotecanTS1 plus irinotecanTS 1 plus irinotecan